Aligos Therapeutics, Inc. (ALGS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Aligos Therapeutics, Inc. (ALGS) closed at USD 5.23 on 2026-10-14, a change of -43.9 % over the past year, with a market capitalization of USD 33.66M.

Aligos Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Aligos Therapeutics, Inc. key figures

Previous close

USD 5.23 (2026-10-14)

1-year change

-43.9 %

Market cap

USD 33.66M

Enterprise value

USD 6.78M

P/E ratio (trailing)

-0.76

P/E ratio (forward)

-1.03

EPS (trailing)

-7.11

EPS (forward)

-5.25

PEG ratio

n/a

Price to book

1.05

Revenue growth

2,778.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

14.01

Employees

82

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Aligos Therapeutics, Inc. and compare it with other stocks.